Known contraindication to receive cetuximab or irinotecan at the planned doses
No contraindication for surgery
Known hypersensitivity to the trial drugs or other contraindication to standard “7+3” induction chemotherapy
Subject has known contraindication or allergy to both xanthine oxidase inhibitors and rasburicase
Any medical or physical contraindication, or other inability to undergo hematopoietic progenitor cell (HPC) collection
Surgery, unless documented contraindication
Radiotherapy, unless documented contraindication
Chemotherapy, unless documented contraindication
Contraindication to angiography or chemoembolization medications
History of thromboembolic disease or uterine cancer that is considered a contraindication to tamoxifen
Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
Known contraindication to phosphodiesterase-5 inhibitors (e.g. currently on nitrates)
Any known factors that would pose a contraindication to receiving nivolumab
Subjects with melanoma or with a history of melanoma, invasive squamous cell carcinomas, or aphakia (due to contraindication for use of methoxsalen).
History of documented anaphylaxis or contraindication to any of the study medications
Contraindication to epidural per Pain Service guidelines
All patients with tumors involving the thoracic esophagus must undergo bronchoscopy to document the absence of a fistula no known contraindication to the use of taxanes or platinum compounds
Contraindication to MRI (metal implants)
Contraindication to angiography/embolization procedure based on judgment of the treating investigator
Contraindication to MRI
Any known hypersensitivity or contraindication to the components of the study drug AZD1775
No known hypersensitivity or contraindication to the components of study treatment (M6620 [VX-970], gemcitabine)
Any known hypersensitivity or contraindication to the components of the study drug AZD1775
Participant has a contraindication to biopsy
Medical contraindication to receipt of radiotherapy
No contraindication to tumor biopsy at time of study enrollment
Active venous thrombosis with contraindication for anticoagulation
Patients in whom there is a medical contraindication or potential problem in complying with the requirements of the protocol, in the opinion of the investigator.
For Cohorts 1, 3 and 4, contraindication to chemotherapy as first-line therapy due to patient age, comorbidity or patient preference
Contraindication to any concomitant medication, including antivirals, anticoagulation prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapy
Contraindication to RPFNA including breast implant(s), bilateral radiation, anticoagulation (excluding those on 81 mg aspirin)
Contraindication to receiving radiotherapy
Known contraindication for topotecan or temozolomide
Patients with contraindication to use leucovorin calcium (calcium folinate), 5-fluorouracil, and oxaliplatin (FOLFOX) chemotherapy and pelvic radiation.
Contraindication to cyclophosphamide or fludarabine chemotherapy
Extensive loculations or hydropneumothorax or other contraindication to pleurodesis
Contraindication or precaution for enzalutamide
Has a contraindication (sensitivity or allergy) to trimethoprim/sulfamethoxazole and ampicillin.
Any condition that would be a contraindication to receiving trastuzumab as described in the approved local label or a condition that would prevent treatment with the physician's choice of chemotherapy
Contraindication to receive radiotherapy
Contraindication to IV contrast
Contraindication to cyclophosphamide or fludarabine chemotherapy
Patients with contraindication to thromboprophylaxis
A known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT imaging
Any contraindication to therapy with nivolumab
Medical contraindication to radiation treatment (e.g. active systemic sclerosis, other uncontrolled autoimmune condition)
Contraindication to angiography/embolization including:\r\n* Patients cannot receive contrast:\r\n** Severe allergic reaction to contrast despite premedication\r\n** Poor renal function not on dialysis\r\n* Other, based on judgment of the investigator
Colorectal patients must have received prior fluorouracil (5FU), irinotecan and oxaliplatin (any combination) or have a contraindication to receiving these agents
CRITERIA FOR SCREENING: Any known contraindication to leukapheresis
CRITERIA FOR SCREENING: Any known and irreversible contraindication to huJCAR014 therapy
CRITERIA FOR LEUKAPHERESIS AND PRE-THERAPY EVALUATION: History or presence of clinically relevant central nervous system (CNS) pathology that, in the opinion of the PI or designee, is a contraindication to lymphodepleting chemotherapy or huJCAR014 infusion
Contraindication to the use of PTX
Has a history or current evidence of physical or physiological contraindication to participation in this study, at the discretion of the treating investigator
Patients with any contraindication to receiving rhuGM-CSF based products
Absence of contraindication for Ommaya reservoir
Any contraindication to the combination anti-cancer agent as per local prescribing information
Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines
Unable to undergo MRI of the brain (i.e. pacemaker or any other contraindication for MRIs)
Active uncontrolled infection that would be a contraindication to safe use of high-dose therapy
Contraindication to any concomitant medication, including pre-medications or hydration given prior to therapy
No contraindication to be on a minimum of 81 mg aspirin a day (or other anticoagulant therapy as prescribed) for thromboembolism prophylaxis
Contraindication to intravenous (IV) contrast
Have a contraindication to post-ASCT maintenance lenalidomide
Patients with clinical contraindication against lumbar puncture or Ommaya placement are NOT eligible for either Stratum
Contraindication to repeat breast biopsy (neoadjuvant chemotherapy group)
Patients who have contraindication to cyclophosphamide chemotherapy
Contraindication for undergoing MRIs
No contraindication to receiving radiotherapy and no known allergy to components of fresolimumab
Subjects with a contraindication to MR-HIFU.
Patients who cannot obtain a contrast-enhanced MRI or CT myelogram due to allergy, renal failure or other medical contraindication
Contraindication to general anesthesia
Contraindication to MRI scans or intravenous contrast
Medical contraindication to the use of varenicline OR nicotine patch
Medical contraindication to the use of bupropion
Any contraindication to external beam radiotherapy
Patients with documented contraindication to anticoagulation therapy such as heparin induced thrombocytopenia or a documented coagulopathy or hematologic disorder that would contraindicated undergoing treatment and use of the associated anticoagulant agents required during treatment
Patients with any contraindication to receiving rhuGM-CSF based products
Contraindication to receiving HCQ or TACE
Contraindication to or unwillingness to undergo study related procedures including a repeat bronchoscopy
Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
The patient has a contraindication (e.g. sensitivity/allergy) to both trimethoprim/sulfamethoxazole and ampicillin
Contraindication or unwillingness to undergo multiple CT scans
Must have no contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment.
Contraindication to receiving radiotherapy or TACE
Presenting with a general or visceral contraindication to intensive treatment including:
Known contraindication or hypersensitivity to any component of bevacizumab
Patient has a known hypersensitivity or contraindication to study products that, in the opinion of the investigator, cannot be adequately pre-medicated
Patient with contraindication for imaging with MRI
MATCHED RELATED DONOR: History of other medical conditions that in the opinion of PI constitute a contraindication to donation
HAPLOIDENTICAL RELATED DONOR: History of other medical conditions that in the opinion of PI constitute a contraindication to donation
Requires treatment with other medications that cannot be stopped and for which there is a known contraindication to co-administration of one or more of the study drugs.
Contraindication to both CT and MRI contrast agents
Have known contraindication to Gd-MRI.
DONOR: No contraindication to the administration of filgrastim (G-CSF)
Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment.
Medical contraindication to apheresis
Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
Patients who have a contraindication to any of the required concomitant drugs or supportive treatments (including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment) are NOT eligible for participation
Contraindication to haploidentical HCT as defined by the Investigator
Patients with contraindication for treatment by laparoscopy
Any known hypersensitivity or contraindication to the components of the study drug AZD1775
Known contraindication to aromatase inhibitor or SERM therapy
Any known hypersensitivity or contraindication to the components of the study drug AZD1775 or olaparib.
Part 2: have a major contraindication to MP (e.g., allergy/hypersensitivity to study medications or their constituents), or conditions making adherence difficult as determined by the attending physician
Has a contraindication to administration of amoxicillin, ampicillin, ciprofloxacin, erythromycin, gentamycin, penicillin, trimethoprim/sulfamethoxazole, and vancomycin
Has contraindication to administration of non-steroidal anti-inflammatory drugs (NSAIDS)
Patients with a contraindication to contrast-enhanced MRI
Participants in whom there is a medical contraindication or potential problem in complying with the requirements of the protocol, in the opinion of the investigator
Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
Any medical or physical contraindication or any other inability to undergo HSPC collection
Any medical or physical contraindication or other inability to undergo HSPC collection
Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all available anti-microbial drugs or intolerance to IV hydration due to pre-existing pulmonary or cardiac impairment
Contraindication to cisplatin chemotherapy or plans to alter or reduce cisplatin therapy
Known contraindication to dexamethasone (allergic reaction or systemic fungal infection)
For the phase II portion, patients must have histologically and/or cytologically confirmed metastatic colorectal carcinoma that has progressed on, is intolerant of, or is inappropriate for all standard therapies; subjects must have been treated with a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan and bevacizumab or have contraindication to such treatment; prior epithelial growth factor receptor (EGFR)-targeting agent (or contraindication to these drugs) is required for subjects with K-Ras wildtype tumors
Any contraindication to the use of cisplatin, carboplatin, or paclitaxel chemotherapy
Prior systemic regimens must include previously approved therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF therapy (if no contraindication); and if negative for KRAS, NRAS, and BRAF mutations and no contraindication, an anti-epidermal growth factor receptor (EGFR) therapy; and progressed after the last administration of approved therapy.
Subjects with bone metastases should be treated with intravenous bisphosphonates or subcutaneous denosumab (or investigator preferred standard of care) prior to and/or during the trial, unless there is a contraindication or subject intolerance to these therapies. For patients who are normocalcemic, therapy can be initiated at the time the patient initiates study drug
Contraindication to treatment for TE prophylaxis
Contraindication to any drug in the chemotherapy regimen, and specifically
Patients must have been previously treated with a taxane except in cases of contraindication (e.g. poor performance status, age or patient choice)
DONOR: Any contraindication to the administration of subcutaneous G-CSF at a dose of 16 mg/kg/day for 5 consecutive days
Has a contraindication to administration of ampicillin or trimethoprim/ sulfamethoxazole.
Any contraindication to oral agents.
Known or suspected hypersensitivity to ofatumumab or SB-485232 that in the opinion of the investigator is a contraindication to their participation in the study
Contraindication to any concomitant medication, including antivirals, anticoagulation prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapy
Medical contraindication to undergoing MR imaging
Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, or antiviral drugs
Contraindication to use of gadolinium-based intravenous contrast, including life-threatening allergy or compromised renal function (creatinine > 2.0)
Contraindication to all available herpes simplex virus (HSV)/varicella prophylactic antiviral drugs
Patients who have contraindication to MRI
For stratum C, patients must have received prior anthracycline therapy anthracycline (or have a contraindication to anthracycline) or gemcitabine-based therapy (or have a contraindication to gemcitabine)
Contraindication to dexamethasone or any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs, or intolerance to hydration due to pre-existing pulmonary or cardiac impairment
Has a contraindication to administration of trimethoprim/sulfamethoxazole or ampicillin.
Subject has a contraindication to receiving IM injections (eg, bleeding disorders, anticoagulant use).
Subjects with a known allergy to polyethylene glycol hydrogel (spacer material) or contraindication to spacer products (Duraseal or SpaceOAR)
Any contraindication to ECP, i.e. contraindication to heparin or methoxsalen (8-MOP)
Has a contraindication to administration of trimethoprim/sulfamethoxazole or ampicillin.
Subject has known contraindication or allergy to both xanthine oxidase inhibitors and rasburicase.
Clear contraindication for systemic corticosteroids (diabetes mellitus is not per se a clear contraindication);
Contraindication to any of the required concomitant drugs or supportive treatments or intolerance to hydration due to preexisting pulmonary or cardiac impairment
Patients with contraindication to thromboprophylaxis
Contraindication to MRI
No contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
Participants with contraindication to RT while adjuvant RT is clinically indicated
Contraindication to any concomitant medication, including antivirals or anticoagulation
Contraindication to any concomitant medication, including antivirals, anticoagulation prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapy.
Has a known hypersensitivity, intolerability or contraindication to any component of study treatment, including premedication
Contraindication to any concomitant medication, including antivirals or anticoagulation
Contraindication to heparin as per NCCN guidelines
Contraindication to corticosteroids
Contraindication to EUS-guided needle puncture into the pancreas
Medical contraindication to biopsy of target lesion
Patients with contraindication to steroid use
Contraindication to chemotherapy or radiation
Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
Any contraindication or known allergy or hypersensitivity to any study drugs
Contraindication to gadolinium-enhanced MRI imaging
Patients with a contraindication (e.g. sensitivity/allergy) to trimethoprim/sulfamethoxazole or ampicillin
Contraindication to any concomitant medication, including antivirals or anticoagulation
Subjects with bone metastases should be treated with intravenous bisphosphonates or subcutaneous denosumab (or investigator preferred standard of care) prior to and during the trial, unless there is a contraindication or subject intolerance to these therapies
Any contraindication for TACE.
Any contraindication for doxorubicin administration:
Subjects with an absolute contraindication to corticosteroid administration
Patients with locally advanced BCC are required to have disease that is considered inoperable due to significant functional compromise or to have a medical contraindication to surgery
Previous treatment with fluoropyrimidine-, oxaliplatin- and irinotecan- based chemotherapy, an anti-VEGF therapy (if no contraindication) and if KRAS wild type and no contraindication, an anti-EGFR therapy.
Any known hypersensitivity or contraindication to the components of study treatment
Known contraindication to standard-of-care sorafenib including allergic reaction, pill swallowing difficulty, uncontrolled hypertension or history of cardiac disease, significant GI bleed within 30 days, renal failure including dialysis
Contraindication to propranolol, etodolac
Patients with any known contraindication to treatment with, including hypersensitivity to quinacrine or erlotinib
Contraindication to concomitant anticoagulation prophylaxis
Any other contraindication listed in the local labeling of dalteparin, enoxaparin, or edoxaban;
Any contraindication to MRI examination
Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
Any contraindication, allergy, or hypersensitivity to rociletinib, trametinib, or excipients
Contraindication to receive vincristine or any planned protocol-specified chemotherapy
Known contraindication to intravenous gadolinium contrast administration (e.g., renal impairment, known allergy); standard institutional policies on gadolinium and renal function will be followed
Contraindication to potential treatment agents
Patient must have no contraindication for CT with iodinated contrast
Known hypersensitivity or contraindication to study drugs, oxazolidinones, or quinolones.
Known contraindication to dexamethasone
Contraindication to any of the required concomitant drugs, including antiviral (e.g. Valacyclovir)
Contraindication to any of the required concomitant drugs or supportive treatments, including antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
Known sensitivity or contraindication to any component of study treatment
Contraindication for all comparators:
Patients with contraindication to dexamethasone.
Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment.
Any contraindication to gemcitabine therapy
Known or suspected hypersensitivity to ofatumumab or bendamustine that in the opinion of the investigator is a contraindication to their participation in the present study.
Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents, or other contraindication to gadolinium contrast and other known contraindication to MRI;
Contraindication for nicotine patch use
Physical or psychological contraindication to participation at the discretion of the treating physician
History of documented anaphylaxis or contraindication to any of the study medications
PHASE II: Any medical contraindication to exercise according to a physician or physician’s designee
Connective tissue disorders, e.g. scleroderma, that in the opinion of the treating physicians is a contraindication to radiation therapy
Contraindication or allergy to intravenous lidocaine
Subject, as deemed by treating investigator has contraindication to endoscopy or Spray Cryotherapy Procedure.
Any contraindication to cardiac stress testing
Patients with any pre-existing medical conditions that would be a contraindication to exercise
Absolute contraindication to intravenous iodinated contrast (history [Hx] of significant previous contrast reaction, not mitigated by appropriate pre-medication)
Patients with a history of hypersensitivity to dexamethasone or having any contraindication to physical activity as determined by the treating physician
Major contraindication to methylphenidate i.e. hypersensitivity
Contraindication to gadolinium contrast administration during MR imaging, such as allergy or insufficient renal function
Major contraindication to fish oil i.e. hypersensitivity to fish/oil or physical activity
Medical contraindication to exercise
Contraindication to use of non-steroidal anti-inflammatory drug (NSAID), acetaminophen or IV opioids
Pregnant patients will not be included in the study as pregnancy is a relative contraindication for these types of surgical procedures
Major contraindication to ginseng: allergy/hypersensitivity to Panax species or their constituents (history of arrhythmias, agitation, or motor tics, or severe angina pectoris)
Contraindication to placement of an IPC (e.g., uncorrected coagulopathy)
Known contraindication to receiving G-CSF
Hypersensitivity/allergy or contraindication to any component of the stent, delivery system, or medication required to complete the procedure,which in the investigator's opinion cannot be adequately premedicated
Allergy or other contraindication to morphine sulfate
Patients with allergy, hypersensitivity or other contraindication to dapsone, sulfa antibiotics, or excipients of the dapsone gel product
The allogeneic PBSC donor has a contraindication to statin treatment
Participant has allergy or other contraindication for morphine or gabapentin therapy
Do not have a contraindication to MRI (i.e., pacemaker)
Contraindication to gadolinium (Gd) contrast agents
Patients with contraindication to the intravenous use of iodinated contrast agent (i.e. allergy to iodinated contrast or severely impaired renal function with a creatinine level >= 1.3)
Women who have a contraindication to the intravenous use of iodinated contrast agent (i.e., allergy to iodinated contrast or severely impaired renal function with a creatinine level >= 1.3)
Contraindication for the nicotine patch (e.g., heart attack, angina, skin allergies) unless a doctor’s note is provided.
Contraindication to NRT;
The allogeneic PBSC donor has a contraindication to statin treatment
Medical contraindication to receipt of radiotherapy
Any contraindication for GVHD prophylaxis with mycophenolate mofetil, cyclosporine A, or tacrolimus
No known contraindication to NSAID use
Have no contraindication to NRT
Have a contraindication to NRT
Patients who have a contraindication to radiation therapy
Presence of any contraindication for a neurosurgical procedure
contraindication to anticoagulant therapy
Has contraindication to MRI contrast
Women who have a contraindication to the intravenous use of iodinated contrast agent (i.e., allergy to iodinated contrast or severely impaired renal function with a creatinine level > 1.3 or estimated glomerular filtration rate [eGFR] >= 45)
Patients with a contraindication to sedation or general anesthesia
Patients with a contraindication to sedation or general anesthesia
Patient must not have contraindication to iodinated contrast
Contraindication to MRI
Contraindication to PET
Excluded from this study will be prisoners, pregnant women, patients with a contraindication for additional lung biopsies, and patients who cannot give informed consent (language barrier, cognitive impairment, etc.)
Subjects who have a contraindication for 3Tesla (3T) MRI, or have an allergy to gadolinium containing contrast material
Patients with a contraindication to gadolinium based contrast agents, including allergy or impaired renal function (per UW health guidelines)
Any other contraindication to CT with iodinated contrast, as CT with contrast will be used in the study
Contraindication to Lasix
Contraindication to MRI scan (i.e. due to cardiac pacemaker)
Any contraindication to bronchoscopy, for example:
Contraindication to general anesthesia
Inability or contraindication to undergo transcatheter arterial embolization
Contraindication to CT or MRI contrast
Patients with a contraindication to contrast-enhanced MRI
Patients with a malignancy within the past 3 years for which study drugs or a prostatectomy is a contraindication
Known hypersensitivity to glucagon (contraindication for glucagon IV, required for endorectal MRI only)
Pheochromocytoma, insulinoma or galactosemia (contraindication for glucagon IV, required for endorectal MRI only)
Insulin?dependent diabetes (contraindication for glucagon IV, required for endorectal MRI only)
Any contraindication to gadolinium intravenous contrast as per standard Department of Radiology contrast guidelines
Any contraindication to gadolinium intravenous contrast as per standard Department of Radiology contrast guidelines
Contraindication to MRI
Contraindication to PET
Subject who is deemed by the treating physician to have a contraindication to definitive treatment
Subjects with a contraindication to receiving gadolinium containing contrast for the MRI
Contraindication to MRI or history of adverse reaction to gadolinium
Contraindication for MP MRI
Patients who have presence of a known contraindication to DCE-MRI may not participate in that portion of the study:\r\n* Known reaction to gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA), contrast agent \r\n* Chronic kidney disease\r\n* Nursing women
Contraindication to use of gadolinium based intravenous contrast, including life threatening allergy or compromised renal function (creatinine > 2.0)
Known intolerance, hypersensitivity, or contraindication to glucocorticoids.
Contraindication to any of the required concomitant drugs or supportive treatments.
Contraindication or allergy to Feraheme (based on insert)
Contraindication to MRI
Contraindication to potassium iodide
Contraindication to prostate mpMRI (renal failure, hip prosthesis, pacemaker, etc)
Contraindication to prostate biopsy via transrectal or transperineal approaches (including coagulopathy)
Contraindication for or inability to tolerate MRI examination
Contraindication to use of fluoropyrimidines as a radiosensitizing agent
Contraindication to prostate biopsy
Patient with known severe adverse drug reaction or contraindication to Gadolinium-Based Contrast Agent
Contraindication to MRI (metal implants)
Claustrophobia or any other contraindication to MRI imaging evaluated by a standardized safety questionnaire
Contraindication for oral potassium iodine administration
Patient who has a contraindication to endoscopy
Any known hypersensitivity or contraindication to the components of study treatment
Have no contraindication to short-term atorvastatin therapy
History of any condition deemed by the principal investigator to be a contraindication to B-WARM therapy (e.g., skin reaction, dysregulation of thermoregulation, etc)
Any contraindication to dexamethasone or valproic acid such as known allergies or sensitivity
Have a contraindication to NSAIDs at the oncologist’s discretion (i.e., allergy, worsening of ongoing medical problem due to NSAID, low platelet count from chemotherapy, and uncontrolled condition such as hypertension or asthma)
Patients must not have any known contraindication to CSFs prior to registration, including prior hypersensitivity to Escherichia coli-derived proteins, filgrastim, pegfilgrastim, or tbo-filgrastim
Contraindication to test article, constituents, or required concomitant medications